What I have: WWB · dulaglutide.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
What is the correct interpretation, and what is the common misreading?
The relevant arithmetic is that gross mass equals peptide plus counter-ion plus water, and the certificate usually reports only the first indirectly.
Quantification differs by ion: trifluoroacetate by ion chromatography or by fluorine nuclear magnetic resonance, acetate by ion chromatography or by capillary electrophoresis. Neither shows up on a UV chromatogram.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
In practice, net peptide content — the fraction of gross mass that is the peptide itself — is the figure that folds water and counter-ion together and is what you should ask for if you ask for anything.
Peptides from reverse-phase purification with trifluoroacetic acid mobile phases are isolated as trifluoroacetate salts, which is standard synthesis practice.
Absence of a counter-ion figure is an absent measurement rather than a low one.
Water plus counter-ion is why gross mass and peptide mass differ.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe short version: peptides are supplied as salts, the salt is real mass, and neither purity nor a chromatogram will tell you how much of it there is.
Peptides purified by reverse-phase chromatography with a trifluoroacetic acid mobile phase are isolated as trifluoroacetate salts. The trifluoroacetate content depends on the number of basic residues and can run from a few per cent to well over ten by mass on a heavily basic sequence.
It helps to be literal here: trifluoroacetate has documented biological effects at higher concentrations in cell culture, which is the technical reason acetate exchange exists rather than a marketing one.
Counter-ion content scales with the number of basic residues, following directly from charge balance.
Net peptide content varies between lots as the process varies, so one figure does not characterise a supplier.
Purity says nothing about counter-ion. They are unrelated measurements.
Start with which counter-ion the process produced, because trifluoroacetate from reverse-phase purification and acetate from a salt exchange behave differently and are quantified differently.
A supplier who reports both water and counter-ion has given you everything needed to reconcile the vial, and on this site that is a very short list.
Worked reconciliation: a 10 mg vial at four per cent water and eight per cent trifluoroacetate contains 10.0 × 0.88 = 8.8 mg of peptide, a twelve per cent shortfall against label with a perfectly clean purity figure.
Ion chromatography and fluorine NMR are the accepted quantitative methods for trifluoroacetate, and neither is a chromatographic purity method.
The caveat is that a purity figure is completely blind to counter-ion content, and the two are routinely conflated.
Count the basic residues and you can estimate the counter-ion load.
A net-peptide-content figure already accounts for it, which is why net content is the number worth asking for.
Acetate salts are produced by a deliberate ion exchange after purification. The exchange costs a processing step and is the reason acetate-form material is more expensive.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Trifluoroacetate unless a deliberate exchange was done. Ask which.
edited 13 Mar 2026 by priya_menon — removed a claim I could not source
Answer first: the counter-ion is part of the mass you paid for and none of the peptide you wanted, and it can run to several per cent or more.
The number of basic residues drives counter-ion load, because each protonated basic site pairs with one counter-ion. A sequence with several lysines and arginines carries proportionally more.
Trifluoroacetate effects in cell culture are documented and are the technical basis for salt exchange to acetate.
The caveat is that none of this makes a research-grade vial equivalent to a licensed medicine. There is no release testing programme behind it, no pharmacovigilance, and no recourse if it is wrong. Independent testing narrows your uncertainty; it does not eliminate the category difference.
Ask for net peptide content. It folds water and counter-ion into one usable number.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.